Open AccessCost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
Author(s) -
Jayne Palmer,
O. R. Leeuwenkamp
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i20.4793
Subject(s) - everolimus , medicine , neuroendocrine tumors , sunitinib , cost effectiveness analysis , cost effectiveness , oncology , cancer , risk analysis (engineering)
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a relatively rare and heterogenous group of tumors. Currently available treatment options for patients with progressive GEP-NETs include lutetium ( 177 Lu) oxodotreotide ( 177 Lu-Dotatate) and everolimus [as well as sunitinib for patients with pancreatic NETs (P-NETs)].